These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 11477964)

  • 1. Predicting and comparing long-term measles antibody profiles of different immunization policies.
    Lee MS; Nokes DJ
    Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
    Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
    J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroconversion after measles vaccination at nine and fifteen months of age.
    Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
    Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
    Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
    J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained measles elimination in Australia and priorities for long term maintenance.
    Gidding HF; Wood J; MacIntyre CR; Kelly H; Lambert SB; Gilbert GL; McIntyre PB
    Vaccine; 2007 May; 25(18):3574-80. PubMed ID: 17300858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-dose measles vaccination schedules.
    Rosenthal SR; Clements CJ
    Bull World Health Organ; 1993; 71(3-4):421-8. PubMed ID: 8324862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population immunity to measles in the United States, 1999.
    Hutchins SS; Bellini WJ; Coronado V; Jiles R; Wooten K; Deladisma A
    J Infect Dis; 2004 May; 189 Suppl 1():S91-7. PubMed ID: 15106096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in measles and rubella elimination in Iran.
    Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroresponse to the second measles vaccine dose at school entry in Qassim province, Saudi Arabia.
    Khalil MK; Nadrah HM; Al Yahia OA; ElGhazali G
    East Mediterr Health J; 2011 Mar; 17(3):191-5. PubMed ID: 21735958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a measles elimination strategy on measles incidence in Malaysia.
    Saraswathy TS; Zahrin HN; Norhashmimi H; Az-Ulhusna A; Zainah S; Rohani J
    Southeast Asian J Trop Med Public Health; 2009 Jul; 40(4):742-7. PubMed ID: 19842408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles seroepidemiology and decay rate of vaccine-induced measles IgG titers in Taiwan, 1995-1997.
    Lee MS; Chien LJ; Yueh YY; Lu CF
    Vaccine; 2001 Sep; 19(32):4644-51. PubMed ID: 11535312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran.
    Yekta Z; Pourali R; Taravati MR; Shahabi S; Salary S; Khalily F; Farzin A
    East Mediterr Health J; 2009; 15(3):516-25. PubMed ID: 19731767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa].
    Gonçalves G; Tavares F; de Andrade HR
    Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles vaccination effectiveness among children under 5 years of age in Kampala, Uganda.
    Mupere E; Karamagi C; Zirembuzi G; Grabowsky M; de Swart RL; Nanyunja M; Mayanja H
    Vaccine; 2006 May; 24(19):4111-5. PubMed ID: 16554111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.